ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 154 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,775 | -47.8% | 696 | 0.0% | 0.00% | -42.9% |
| Q2 2023 | $14,895 | -47.1% | 696 | 0.0% | 0.01% | -50.0% |
| Q1 2023 | $28,147 | -13.1% | 696 | 0.0% | 0.01% | -17.6% |
| Q4 2022 | $32,378 | -10.1% | 696 | 0.0% | 0.02% | -10.5% |
| Q3 2022 | $36,000 | +9.1% | 696 | 0.0% | 0.02% | +11.8% |
| Q2 2022 | $33,000 | -34.0% | 696 | 0.0% | 0.02% | -26.1% |
| Q1 2022 | $50,000 | -3.8% | 696 | 0.0% | 0.02% | 0.0% |
| Q4 2021 | $52,000 | +30.0% | 696 | 0.0% | 0.02% | +15.0% |
| Q3 2021 | $40,000 | +29.0% | 696 | 0.0% | 0.02% | +25.0% |
| Q2 2021 | $31,000 | -8.8% | 696 | 0.0% | 0.02% | -15.8% |
| Q1 2021 | $34,000 | +17.2% | 696 | 0.0% | 0.02% | +11.8% |
| Q4 2020 | $29,000 | -9.4% | 696 | 0.0% | 0.02% | -19.0% |
| Q3 2020 | $32,000 | -8.6% | 696 | 0.0% | 0.02% | -19.2% |
| Q2 2020 | $35,000 | -2.8% | 696 | 0.0% | 0.03% | -18.8% |
| Q1 2020 | $36,000 | -16.3% | 696 | 0.0% | 0.03% | +3.2% |
| Q4 2019 | $43,000 | – | 696 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 858,811 | $36,156,000 | 10.56% |
| Fairmount Funds Management LLC | 150,433 | $6,333,000 | 2.26% |
| ARMISTICE CAPITAL, LLC | 1,356,000 | $57,088,000 | 1.94% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,775,000 | $74,728,000 | 0.45% |
| Virtus ETF Advisers LLC | 14,321 | $603,000 | 0.25% |
| Granahan Investment Management | 231,071 | $9,728,000 | 0.22% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 248,320 | $10,454,000 | 0.09% |
| ACADIAN ASSET MANAGEMENT LLC | 467,514 | $19,684,000 | 0.08% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 126 | $5,000 | 0.08% |
| AIGEN INVESTMENT MANAGEMENT, LP | 12,854 | $541,000 | 0.07% |